Immunic Inc (IMUX) Stock Analysis
Verdict: AVOID
Positive technical momentum and Phase 3 MS prospects are overshadowed by a critical cash runway deficit and imminent dilution risk.
Investment score: 38/100
Analysis as of
Is Immunic Inc stock worth reviewing? AI model thesis
Immunic shows strong technical momentum but faces a terminal cash crunch without external funding.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Immunic Inc opportunities and risks
What speaks for IMUX
- Vidofludimus Calcium Phase 3 Potential
What speaks against IMUX
- Imminent Dilution/Financing Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IMUX | n/a | 0.0x | 0.4x | 0.0% | 0.0% | -58.5% |
| QTTB | 4.9x | 2.8x | 4.9x | 99.5% | 61.9% | -18.4% |
| GALT | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.3% |
| ABOS | n/a | 0.0x | n/a | 0.0% | 0.0% | -67.9% |
| TNYA | n/a | 601.8x | n/a | 144.9% | -36891.1% | -47.7% |
| PLX | 11.2x | 2.3x | 6.6x | 70.0% | 20.1% | 8.4% |
| Peer median | n/a | 2.3x | n/a | 70.0% | 0.0% | -18.4% |
Frequently asked questions about Immunic Inc (IMUX)
Is IMUX stock a good investment?
The cached TradeMates AI model rates Immunic Inc as AVOID with an investment score of 38/100. Immunic shows strong technical momentum but faces a terminal cash crunch without external funding. This is algorithmic model output, not personal investment advice.
Is IMUX stock a buy?
The TradeMates model verdict for IMUX is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.